Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 591-598

  Dalal, Anand A ^a   Shah, Manan ^b   D'Souza, Anna O ^b   Rane, Pallavi ^c  

^a GLAXOSMITHKLINE   (United States)

^b XCENDA   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

chronic obstructive pulmonary disease; economics; emergency medical services; hospitalization; utilization

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL DEPARTMENT; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTUBATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; TREND STUDY;

AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITAL CHARGES; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; INTUBATION, INTRATRACHEAL; LENGTH OF STAY; MALE; MEDICARE; PATIENT READMISSION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 78650041558     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.521734     Document Type: Article

References (24)

1. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD. Gig Harbor, WA: Medical Communications Resources, Inc.; December 2009. URL: www.goldcopd.com
3. Stuart B, Doshi JA, Briesacher B, et al. Impact of prescription coverage on hospital and physician costs: A case study of Medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther 2004;26: 1688-1699
4. Center on an Aging Society. Chronic obstructive pulmonary disease. A chronic condition that limits activities. Data Profile 2002;6:1-6
5. Gelberg J, McIvor RA. Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: New insights. Drugs Aging 2010;27:367-375
6. Chi MJ, Lee CY, Wu SC. The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI). Arch Gerontol Geriatr 2010; published online 7 May 2010, doi:10.1016/ j.archger.2010.04.017
7. Menzin J, Boulanger L, Marton J, et al. Economic burden of chronic obstructive pulmonary disease in a Medicare population. Respir Med 2008;102:1248-1256
8. Grasso ME, Weller WE, Shaffer TJ, et al. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:133-138
9. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-2658
10. Foster TS, Miller JD, Marton JP, et al. Assessment of the economic burden of COPD in the U.S.: A review and synthesis of the literature. COPD 2006;3: 211-218
11. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: Results from the Confronting COPD Survey. Respir Med 2003; 97(Suppl C):81-89
12. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285
13. Marton JP, Boulanger L, Friedman M, et al. Assessing the costs of chronic obstructive pulmonary disease: The state Medicaid perspective. Respir Med 2006;100:996-1005
14. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in the U.S.: An analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005;2:311-318
15. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613
16. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001;119:344-352
17. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: U.S. Department of Health and Human Services, 2007
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383
19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-1079
20. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital. Treat Respir Med 2006;5:343-349
21. Ward MM, Javitz HS, Smith WM, et al. Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 2000;94: 1123-1129
22. Donaldson GC, Seemungal TAR, Bhownmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852
23. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422
24. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without longacting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74